Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade A 43.555 -0.29% -0.13
ARWR closed down 2.75 percent on Monday, September 28, 2020, on 71 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ARWR trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish -0.29%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.29%
Outside Day Range Expansion -0.29%
Wide Bands Range Expansion -0.29%
Narrow Range Bar Range Contraction -3.03%
NR7 Range Contraction -3.03%
Inside Day Range Contraction -3.03%
Wide Bands Range Expansion -3.03%
Calm After Storm Range Contraction -1.70%
Wide Bands Range Expansion -1.70%
Older End-of-Day Gignals for ARWR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 3 hours ago
10 DMA Resistance about 3 hours ago
Up 1% about 4 hours ago
Fell Below 10 DMA about 4 hours ago
50 DMA Support 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Molecular Biology Infection Genetics Obesity Gene Expression Hepatitis B RNA Molecular Genetics Biochemistry Apoptosis Chronic Hepatitis B Virus Rna Interference Small Interfering Rna

Is ARWR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 73.72
52 Week Low 19.5101
Average Volume 1,522,679
200-Day Moving Average 41.25
50-Day Moving Average 42.49
20-Day Moving Average 40.07
10-Day Moving Average 43.31
Average True Range 3.16
ADX 28.85
+DI 31.08
-DI 20.08
Chandelier Exit (Long, 3 ATRs ) 43.65
Chandelier Exit (Short, 3 ATRs ) 42.33
Upper Bollinger Band 49.03
Lower Bollinger Band 31.10
Percent B (%b) 0.7
BandWidth 44.75
MACD Line 0.84
MACD Signal Line 0.05
MACD Histogram 0.7877
Fundamentals Value
Market Cap 3.27 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -68.25
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.84
Resistance 3 (R3) 47.87 46.52 47.14
Resistance 2 (R2) 46.52 45.46 46.50 46.91
Resistance 1 (R1) 45.10 44.81 44.43 45.07 46.68
Pivot Point 43.75 43.75 43.41 43.73 43.75
Support 1 (S1) 42.33 42.69 41.66 42.30 40.68
Support 2 (S2) 40.98 42.04 40.96 40.45
Support 3 (S3) 39.56 40.98 40.22
Support 4 (S4) 39.53